Featured Research

from universities, journals, and other organizations

Researchers develop new laboratory cell lines to study treatment for anaplastic thyroid cancer

Date:
August 30, 2010
Source:
Mayo Clinic
Summary:
To their deep dismay, researchers discovered several years ago that laboratory samples of anaplastic thyroid cancer they were using to help them find new treatments for this lethal disease were probably some other kind of cancer. It quickly became evident that the situation in their lab was common throughout the world. Up to half of the cell lines that were supposed to originate from patients with this rare thyroid cancer were either colon or melanoma cancer. So, with the cooperation of many researchers nationwide, the researchers set out to create a new set of laboratory ATC cells, derived from tumors donated by patients.

To their deep dismay, researchers at Mayo Clinic discovered several years ago that laboratory samples of anaplastic thyroid cancer (ATC) they were using to help them find new treatments for this lethal disease were probably some other kind of cancer.

It quickly became evident that the situation in their lab was common throughout the world. Up to half of the cell lines that were supposed to originate from patients with this rare thyroid cancer were either colon or melanoma cancer.

So, with the cooperation of many researchers nationwide, the Mayo researchers set out to create a new set of laboratory ATC cells, derived from tumors donated by patients.

In the Aug. 25 online issue of the Journal of Clinical Endocrinology & Metabolism, the researchers report successful creation of four new ATC cell lines, each with a different set of molecular mutations driving this aggressive cancer. Survival for ATC patients is typically brief, three to four months on average, as illustrated by the speculated ATC diagnosis and death in 2005 of Chief Justice of the United States William Rehnquist.

The researchers are sharing the new ATC cells with researchers internationally who need them, says the study's co-principal author, John Copland, Ph.D., a cancer biologist at the Mayo Clinic campus at Jacksonville.

"Since cell lines are immortal and can live forever, they are critical to research and a major issue is cell line contamination leading to misidentification and drawing incorrect conclusions for specific cancers," Dr. Copland says. "We provide higher standards for characterizing new cell lines at the genomic and molecular level that can be traced back to the originating tumor tissue."

The study shows detailed molecular fingerprinting that links genetic mutations found in the patients' tumors to the cell lines that are derived from these tumors. If any question arises in the future as to whether the newly created cell lines have become contaminated by other cancers, researchers can use the Mayo Clinic data to confirm the origin of the cells.

This matters, the researchers say, because advances in cancer treatment depend on the testing that is first undertaken in cell lines, and, therefore, the cell lines must be pure. "We want to test different drugs against each cell line in which specific pathways are activated to see the effects," says endocrinologist Robert Smallridge, M.D., the other co-principal author. "Each of those different combinations of molecular abnormalities is going to generate a different set of potential targets that can be attacked through drug therapy."

Dr. Smallridge believes that within a few years it will be possible to genetically analyze each patient's ATC tumor in real time, and match its molecular profile to potential drugs. "No two tumors may match each other, but by understanding through a systems biology approach the multiple pathways that are active in the cancer, and then using a combination of drugs that inhibit these pathways simultaneously, we will begin to make progress against this cancer," he says.

This is the essence of "bench-to-bedside" therapy, according to the study's lead investigator, Laura Marlow, M.S.

According to Marlow, not only did the study report development of the cell lines, a project she led, it also tested five different drugs in these new cells lines for potential benefit. The researchers found that all of these agents, everything from an approved cholesterol lowering agent to experimental transferase inhibitors, reactivated a tumor suppressor gene called RhoB, leading to growth suppression.

Mayo researchers, led by Dr. Copland, had earlier discovered that RhoB function was missing in ATC cells, as it is in some other cancers. Dr. Smallridge is currently conducting a phase I clinical trial testing an agent that can turn the tumor suppressor function back on.

Because thyroid cancers are uncommon and anaplastic thyroid cancer is exceedingly rare -- fewer than 600 new ATC cases a year in the U.S. -- Dr. Smallridge asks every patient having surgery for thyroid cancer at Mayo Clinic for a tumor sample. Other surgeons around the country have sent Marlow tumor samples in her quest to create new cell lines for thyroid cancer.

"This work defines the importance of collaborations across institutions to collect tissues for a very rare cancer," Dr. Copland says.

Using tumor samples from this collaboration, it took two years and many tries to create the four new lines, Marlow says. "These cells are very difficult to grow and to maintain because of their chromosomal instability," she says. Marlow had to derive a new formula for the media that the cells live on in their culture dishes, a recipe that is special for this kind of cancer and which is reproduced in the study publication. The article also identifies multiple genetic and phenotypic tests that will uniquely identify each cell line now and in the future, she says.

The study was funded in part by grants from the National Institutes of Health/National Cancer Institute, the Mayo Clinic Research Committee, and the Florida Department of Health's Bankhead-Coley Cancer Research program.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Researchers develop new laboratory cell lines to study treatment for anaplastic thyroid cancer." ScienceDaily. ScienceDaily, 30 August 2010. <www.sciencedaily.com/releases/2010/08/100825093251.htm>.
Mayo Clinic. (2010, August 30). Researchers develop new laboratory cell lines to study treatment for anaplastic thyroid cancer. ScienceDaily. Retrieved October 23, 2014 from www.sciencedaily.com/releases/2010/08/100825093251.htm
Mayo Clinic. "Researchers develop new laboratory cell lines to study treatment for anaplastic thyroid cancer." ScienceDaily. www.sciencedaily.com/releases/2010/08/100825093251.htm (accessed October 23, 2014).

Share This



More Health & Medicine News

Thursday, October 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Fears Keep Guinea Hospitals Empty

Ebola Fears Keep Guinea Hospitals Empty

AP (Oct. 23, 2014) Fears of Ebola are keeping doctors and patients alike away from hospitals in the West African nation of Guinea. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
More People Diagnosed With TB In 2013, But There's Good News

More People Diagnosed With TB In 2013, But There's Good News

Newsy (Oct. 22, 2014) The World Health Organizations says TB numbers rose in 2013, but it's partly due to better detection and more survivors. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins